The biotech company dosed its first patient in a phase 1 clinical trial Nov. 30 at MD Anderson to test NTX1088, a protein blocker targeting locally advanced and metastatic solid tumors.
“NTX1088’s triple mechanism of action represents a unique approach to treating challenging cancers, and we are excited by its potential to address a range of treatment-resistant tumors,” said Ross Barrett, a founder and managing partner of Cancer Focus Fund, in a Nov. 30 Nectin news release.
The funding round was led by Israel Biotech Fund and Peregrine Ventures. Cancer Focus Fund also partners with New Orleans-based Ochsner Health and LSU Health Shreveport (La.).
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
